The growing global burden of colorectal cancer (CRC), particularly in low- and middle-income countries (LMICs) like Nigeria, has underscored the urgent need for innovative approaches to early detection and treatment. Early detection is widely regarded as the single most effective way to improve survival rates and reduce the devastating impact of this preventable disease. In Nigeria, where the incidence of CRC is rising, early diagnosis and cutting-edge treatments are now more accessible than ever, offering hope for better outcomes and a future where colorectal cancer can be managed more effectively.
Dr. T. Peter Kingham, a renowned Hepatobiliary Surgeon and Professor at Memorial Sloan Kettering Cancer Centre (MSKCC), underscored these benefits during a recent lecture in Lagos. The event was organised by MedServe in collaboration with the Memorial Sloan Kettering Cancer Centre (MSKCC) and the Africa Research Group for Oncology (ARGO). He shared insights into the latest advancements in early detection and treatment, emphasising that with the right tools, CRC could be significantly reduced in the country. One of the most powerful tools in the fight against colorectal cancer is early diagnosis. When caught early, CRC is one of the most treatable forms of cancer, with survival rates dramatically improving through timely intervention. However, in many parts of Nigeria, access to reliable screening methods remains a significant challenge, leading to late-stage diagnoses that are harder and more expensive to treat.
Dr. Kingham highlighted promising new approaches to early detection that could change the game in Nigeria. Urine metabolite testing and point-of-care blood tests are two such innovations that could make screening for CRC easier, faster and more affordable. These technologies allow for early diagnosis in resource-limited settings, without the high costs and logistical challenges associated with traditional methods like colonoscopy. By detecting CRC at its earliest stages, these methods could help reduce the need for invasive procedures, ultimately leading to lower healthcare costs and improved patient outcomes. The key benefit of early diagnosis, Dr. Kingham pointed out, is the potential to treat patients before cancer spreads, resulting in less aggressive treatments and fewer complications. As he explained, “In many cases, when colorectal cancer is caught early, patients can avoid chemotherapy or surgery altogether, leading to better quality of life and lower healthcare expenses.”
Read Also: Living in fear of herders and kidnappers
Another major benefit of early detection is the ability to apply the latest advancements in treatment, offering more effective options for patients. Dr. Kingham shared exciting developments in the treatment of colorectal cancer, particularly the rise of immunotherapy. For patients with mismatch repair-deficient (MMRd) CRC, PD-1 blockade immunotherapy has shown remarkable success in clinical trials. In some cases, this innovative treatment has led to complete remission of localised rectal cancer, eliminating the need for traditional therapies such as chemotherapy, radiation, or surgery. These breakthroughs are especially significant in LMICs, where resources and access to advanced cancer treatments are often limited. The ability to offer less invasive and more effective treatments could revolutionize care, ensuring that more patients benefit from cutting-edge therapies, even in resource-constrained settings like Nigeria. “Immunotherapy represents a major step forward. By using the body’s immune system to target cancer, we can potentially reduce the reliance on toxic treatments and provide patients with a better quality of life,” said Dr. Kingham.
For Nigeria, where cancer treatment options can be costly and difficult to access, these new therapies offer a chance to provide more personalised and effective care. If these immunotherapies become widely available, they could drastically improve patient outcomes and reduce the overall cost burden of treating advanced cancer. Dr. Kingham also highlighted the importance of international collaboration in bringing these benefits to patients in Nigeria. Through partnerships between organisations like MSKCC, MedServe and ARGO, ongoing research is already paving the way for innovative cancer care solutions in the country. One such initiative includes a pilot study on the use of PD-1 blockade therapy for metastatic and localized rectal cancer in Nigerian patients. “This research is vital for ensuring that new treatments can be adapted to meet the unique needs of patients in Nigeria. It’s through collaboration that we can address the gaps in care and create context-specific solutions that improve outcomes for patients in LMICs.”
The study, along with other collaborative projects, will provide critical data that could influence future treatment protocols and lead to more effective, localised cancer care strategies in Nigeria. This partnership-driven approach is helping to bridge the gap between cutting-edge research and the practical application of these advances in Nigerian healthcare settings. Beyond the technical advancements in screening and treatment, experts are also emphasizing the importance of public awareness and education. CRC remains under-recognized in many parts of Nigeria, with many people unaware of the signs, symptoms, and the importance of early detection. This lack of awareness often leads to late-stage diagnoses, which are harder to treat and result in poorer outcomes.
Dr. Kingham, along with Nigerian specialists like Prof. Olusegun Isaac Alatise and Dr. Adedapo Osinowo, urged the need for public education campaigns aimed at increasing awareness about CRC and encouraging regular screening. By educating the public and healthcare professionals about the importance of early diagnosis, more patients will seek help at the first sign of symptoms, improving the chances of successful treatment. “Education is key,” said Prof. Alatise. “When people understand the importance of early detection and seek care early, we can reduce the number of patients presenting with advanced-stage cancer and offer them better treatment options.”
The benefits of early detection and treatment are clear: better survival rates, reduced treatment costs, and improved quality of life for patients. As Nigeria and other LMICs continue to confront the rising threat of colorectal cancer, the path forward lies in embracing these innovations in screening and treatment. With international collaboration, new technologies, and a growing awareness of the disease, there is real hope that colorectal cancer can be managed more effectively, saving lives and improving healthcare outcomes for millions of people.